ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
6,045.26
0.38%
US Tech 100
21,346.40
0.00%
Dow Jones
42,967.62
0.24%
Brent Oil
72.685
3.98%
Bitcoin
104,987.29
-0.89%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Kiniksa Pharmaceuticals International PLC (KNSA) Quote

Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals International PLC (KNSA)

NASDAQ
27.73
0.00
(0.00%)
Closed June 13 4:00PM
15 min delayed - Upgrade to Realtime
0.00
0.00
(0.00%)
After Hours: -
15 min delayed - Upgrade to Realtime

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
27.73
Bid
27.65
Ask
28.17
Volume
-
0.00 Day's Range 0.00
17.38 52 Week Range 30.69
Market Cap
2.023B
Previous Close
27.73
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
640,499
Shares Outstanding
72,970,967
Dividend Yield
-
PE Ratio
-46.85
Earnings Per Share (EPS)
-0.59
Revenue
423.24M
Net Profit
-43.19M

About Kiniksa Pharmaceuticals International PLC

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurre... Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its clinical-stage product candidates include Rilonacept, for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; Vixarelimab; and KPL-404. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kiniksa.com
Headquarters
London, Gbr
Founded
-
Kiniksa Pharmaceuticals International PLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker KNSA. The last closing price for Kiniksa Pharmaceuticals was $27.73. Over the last year, Kiniksa Pharmaceuticals shares have traded in a share price range of $ 17.38 to $ 30.69.

Kiniksa Pharmaceuticals currently has 72,970,967 shares outstanding. The market capitalization of Kiniksa Pharmaceuticals is $2.02 billion. Kiniksa Pharmaceuticals has a price to earnings ratio (PE ratio) of -46.85.

Ask ADVFN Intelligence (AI)

KNSA Latest News

More News

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
June 11 2025
KNSA (0.00%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
June 10 2025
KNSA (0.00%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
June 09 2025
KNSA (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 05 2025
KNSA (0.00%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
June 05 2025
KNSA (0.00%)

Form 8-K - Current report
Edgar (US Regulatory)
June 05 2025
KNSA (0.00%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
June 03 2025
KNSA (0.00%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
June 03 2025
KNSA (0.00%)

Form 8-K - Current report
Edgar (US Regulatory)
June 03 2025
KNSA (0.00%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.65-5.6160653505829.3830.6927.6584052629.38474144CS
41.847.1069911162625.8930.6925.467819428.23558593CS
124.0817.251585623723.6530.6918.25564049924.81875071CS
267.6438.028870084620.0930.6917.8260843222.60536405CS
528.8546.87518.8830.6917.3850503423.0406891CS
15619.64242.7688504338.0930.697.843131718.45279173CS
2606.3829.882903981321.35337.3641957917.3406709CS

KNSA - Frequently Asked Questions (FAQ)

What is the current Kiniksa Pharmaceuticals share price?
The current share price of Kiniksa Pharmaceuticals is $ 27.73
How many Kiniksa Pharmaceuticals shares are in issue?
Kiniksa Pharmaceuticals has 72,970,967 shares in issue
What is the market cap of Kiniksa Pharmaceuticals?
The market capitalisation of Kiniksa Pharmaceuticals is USD 2.02B
What is the 1 year trading range for Kiniksa Pharmaceuticals share price?
Kiniksa Pharmaceuticals has traded in the range of $ 17.38 to $ 30.69 during the past year
What is the PE ratio of Kiniksa Pharmaceuticals?
The price to earnings ratio of Kiniksa Pharmaceuticals is -46.85
What is the cash to sales ratio of Kiniksa Pharmaceuticals?
The cash to sales ratio of Kiniksa Pharmaceuticals is 4.78
What is the reporting currency for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals reports financial results in USD
What is the latest annual turnover for Kiniksa Pharmaceuticals?
The latest annual turnover of Kiniksa Pharmaceuticals is USD 423.24M
What is the latest annual profit for Kiniksa Pharmaceuticals?
The latest annual profit of Kiniksa Pharmaceuticals is USD -43.19M
What is the registered address of Kiniksa Pharmaceuticals?
The registered address for Kiniksa Pharmaceuticals is THIRD FLOOR, 23 OLD BOND STREET, LONDON, W1S 4PZ
What is the Kiniksa Pharmaceuticals website address?
The website address for Kiniksa Pharmaceuticals is www.kiniksa.com
Which industry sector does Kiniksa Pharmaceuticals operate in?
Kiniksa Pharmaceuticals operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.05
(0.00%)
0
AACIUArmada Acquisition Corporation II
$ 10.10
(0.00%)
0
AACGATA Creativity Global
$ 0.8231
(0.00%)
0
AACBUArtius II Acquisition Inc
$ 10.36
(0.00%)
0
AACBArtius II Acquisition Inc
$ 10.13
(0.00%)
0

KNSA Discussion

View Posts
Monksdream Monksdream 9 months ago
KNSA inching back up
👍️0
DonDonDonDon DonDonDonDon 4 years ago
No bueno. I guess HGEN's lenzilumab is the best of the anti-GM-CSF drugs for Covid. Lenzilumab's trial showed 54% efficacy. It is guaranteed an EUA within a couple of weeks yet its stock is 20% below where it was a month ago. It dropped 2 days ago because they diluted 5 million shares to pay for manufacturing.

https://www.rheumatologyadvisor.com/home/general-rheumatology/mavrilimumab-outcomes-patients-with-severe-covid19-pneumonia-hyperinflammation/
👍️0
DonDonDonDon DonDonDonDon 4 years ago
It was recently discovered that the protein GM-CSF is the cytokine responsible for severe Covid and death. Kiniksa will surely get a government grant to do an additional trial. Here is a BBC article about the trial that determined that GM-CSF is key to Covid:

https://www.bbc.com/news/health-56352128

Here is an additional article stating that KNSA and HGEN are the two companies with the best GM-CSF drugs to combat Covid:

https://www.clinicaltrialsarena.com/comment/humanigens-and-kiniksas-anti-gm-csf-antibodies-likely-to-garner-a-place-for-nonventilated-covid-19-patients/
👍️0
Femto99 Femto99 4 years ago
PT= $30-40 (by or around March 31st)
https://msmoneymoves.com/2021/02/17/knsa-report/
👍️0
Femto99 Femto99 4 years ago
PDUFA Mar21
👍️0

Your Recent History

NASDAQ
KNSA
Kiniksa Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads